Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

HER2-positive Metastatic Breast Cancer

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Salivary Gland Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Breast Neoplasms

Endometrial Neoplasms

Brain Neoplasms

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Stomach Neoplasms

Breast Neoplasms

Brain Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Anatomic Stage IA Breast Cancer AJCC v8

HER2-positive Breast Cancer

Breast Neoplasms

Clinical Trials

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

HER2 CR

ZEPHIR-02

I-SPY

DARWINII

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

PHERGAIN-2

ATEMPT 2.0: Adjuvant T-DM1 vs TH

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

EndoMAP

BRIDGET

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Opti-HER2

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

G/GEJ

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

ProTarget

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer